Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment.

Article Details

Citation
Copy to clipboard

Nyirjesy P, Schwebke JR

Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment.

Future Microbiol. 2018 Apr;13:507-524. doi: 10.2217/fmb-2017-0270. Epub 2018 Jan 12.

PubMed ID
29327947 [ View in PubMed
]
Abstract

Secnidazole is a next-generation 5-nitroimidazole approved for more than three decades in Europe, Asia, South America and Africa and recently in the USA as a single-dose (2 g) treatment of bacterial vaginosis (BV). Secnidazole is characterized by potent in vitro antimicrobial activity against BV-associated pathogens, as well as prolonged terminal elimination half-life and systemic exposure. These characteristics form the basis of effective and safe treatment of BV with a 2-g single-dose secnidazole regimen, which was recently confirmed in double-blind, placebo-controlled clinical trials conducted in the USA. The option to treat BV with single-dose secnidazole not only cures the primary infection but also may diminish risks of serious sequelae of untreated or undertreated infection.

DrugBank Data that Cites this Article

Drugs